← All trials
NCT06768671
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 30, 2024
- Primary completion
- Mar 27, 2026
- Completion date
- Mar 27, 2026
- First posted
- Jan 10, 2025
- Last posted
- Jan 10, 2025
- Enrollment
- 35
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- MoonLake Immunotherapeutics AGLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.